Global researchers complete world’s first synthetic yeast genome project
Global researchers, led by Australia’s Macquarie University, in a bid to re-engineer life in a laboratory, have completed the world’s first synthetic yeast.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Global researchers, led by Australia’s Macquarie University, in a bid to re-engineer life in a laboratory, have completed the world’s first synthetic yeast.
By Bharti Jayshankar February 1, 2025: A study from the University of Minnesota has revealed a connection between exclusionary discipline (ED) practices in.
HQ Team February 1, 2025: A nine-hour film titled Don’t Look Down, released recently, addresses the problem of smartphone addiction among pre-teens and.
Bharti Jayshankar January 31, 2025: A recent meta-analysis published in BMJ Nutrition Prevention & Health reveals that more than 45% of patients with.
Researchers at Cambridge are developing implants that could help repair damaged brain cells and treat diseases like Parkinson’s.
Vertex Pharmaceuticals Inc.’s non-opioid analgesic to treat moderate to severe acute pain in adults got approval from the US drug regulator.
Britain’s National Health Service will provide a gene therapy that may cure sickle cell disease for patients 12 years and older, according to.
Merck & Co. halted its final-phase study of its experimental drug for pulmonary arterial hypertension after previous studies proved its “robust efficacy,” according.
The UNAIDS has welcomed a move by the United States Secretary of State, Marco Rubio, to approve an “Emergency Humanitarian Waiver” to allow.
Eli Lilly has stopped trials of its investigational drug to treat chronic kidney disease for a “lack of foreseeable clinical benefit,” according to.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com